November 1996
Volume 37, Issue 12
Free
Articles  |   November 1996
Cultured human trabecular meshwork cells express functional alpha 2A adrenergic receptors.
Author Affiliations
  • W D Stamer
    Department of Pharmacology/Toxicology, University of Arizona, Tucson 85721, USA.
  • Y Huang
    Department of Pharmacology/Toxicology, University of Arizona, Tucson 85721, USA.
  • R E Seftor
    Department of Pharmacology/Toxicology, University of Arizona, Tucson 85721, USA.
  • S S Svensson
    Department of Pharmacology/Toxicology, University of Arizona, Tucson 85721, USA.
  • R W Snyder
    Department of Pharmacology/Toxicology, University of Arizona, Tucson 85721, USA.
  • J W Regan
    Department of Pharmacology/Toxicology, University of Arizona, Tucson 85721, USA.
Investigative Ophthalmology & Visual Science November 1996, Vol.37, 2426-2433. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      W D Stamer, Y Huang, R E Seftor, S S Svensson, R W Snyder, J W Regan; Cultured human trabecular meshwork cells express functional alpha 2A adrenergic receptors.. Invest. Ophthalmol. Vis. Sci. 1996;37(12):2426-2433.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: For the treatment of glaucoma, alpha-2 adrenergic receptor (alpha 2-AR) agonists are thought to lower intraocular pressure primarily by decreasing aqueous humor production. Effects on the outflow pathways, however, also may occur. To begin to examine this possibility, the authors characterized the alpha 2-AR subtypes present in cultures of human trabecular meshwork (HTM) cells using both immunofluorescence microscopy and functional measures of alpha 2-AR activation. METHODS: For immunofluorescence microscopy, subtype-specific polyclonal antibodies that recognize each of the human alpha 2-AR subtypes (alpha 2A, alpha 2B, alpha 2C) were used. Functional studies involved the inhibition of forskolin-stimulated cyclic adenosine monophosphate (cAMP) production, the stimulation of mitogen-activated protein (MAP) kinase activity, and the stimulation of mitotic activity as reflected by the expression of proliferating cell nuclear antigen (PCNA). RESULTS: From the immunofluorescence microscopy, there was evidence for the presence of the alpha 2A subtype, but not alpha 2B or alpha 2C subtype, on HTM cells. The administration of the alpha 2-agonist, dexmedetomidine, to HTM cells resulted in a 90% inhibition of forskolin-stimulated cAMP formation, a twofold stimulation of MAP kinase activity, and a threefold increase in the expression of PCNA. Additionally, preincubation of cells with either of the alpha 2-AR-selective antagonists, rauwolscine or atipamezole, reversed the functional effects of dexmedetomidine. CONCLUSIONS: Functional alpha 2A-ARs are present on HTM cells where they may affect the outflow pathway during the treatment of glaucoma with alpha 2-AR agonists.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×